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for AKI [8, [10] [11] [12] , with an increasing trend reported in recent years [1, 8, [12] [13] [14] . The etiology varies and is mainly classified as drug-induced ATIN (D-ATIN), autoimmune/systemic diseases such as tubulointerstitial nephritis and uveitis syndrome (TINU), Sjogren's syndrome, immunoglobulin G4 (IgG4)-related disease, vasculitis, lupus nephritis and rare causes including infection, malignancy and metabolic disorders [1] ; therefore, ATIN can be seen in various clinical units of internal medicine.
The current study was performed on a prospective cohort of 157 cases of biopsy-proven ATIN with various etiologies. These patients were scheduled for follow-up at Peking University First Hospital for 24-108 months post-biopsy, and a changed etiology spectrum was noted over the disease course. Longer-term renal outcomes and possible ways to improve the clinical management were also illustrated.
M A T E R I A L S A N D M E T H O D S

Patients
This was a prospective cohort study of patients who were pathologically diagnosed with ATIN by a native kidney biopsy from 1 January 2005 to 31 December 2013 at Peking University First Hospital. We excluded patients who were younger than 14 years and those with baseline chronic kidney diseases (CKDs). After renal biopsy, patients were enrolled in the ATIN cohort and scheduled for regular follow-up visits at a frequency of one visit per month during the first 6 months and every 3 months thereafter until at least 24 months after renal biopsy. This study was approved by the Committee on Research Ethics of Peking University First Hospital.
Renal pathology
Standard processing of kidney biopsy specimens included light microscopy, immunofluorescence and electron microscopy. For light microscopy, all cases were stained with hematoxylin and eosin, periodic acid-Schiff, Masson's trichrome and Jones methenamine silver. A pathologic diagnosis of ATIN required the presence of prominent interstitial inflammation in the non-fibrotic cortex and tubulitis. Semiquantitative scores for interstitial inflammation, fibrosis, tubulitis and tubular atrophy referred to the Banff Working Classification criteria [15, 16] .
Clinical data and determination of the causes of ATIN
Clinical parameters and laboratory data were documented. Renal dysfunction was evaluated by the serum creatinine (SCr) level. According to the KDIGO criteria, AKI is defined as an abrupt decrease in kidney function occurring within 7 days; acute kidney disease (AKD) describes an acute or subacute loss of kidney function for a duration of between 7 and 90 days after an AKI insult [17, 18] ; and CKD is defined by kidney injury persisting for >90 days. The estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and expressed as milliliters per minute per 1.73 m 2 [19] . Renal tubular function was determined by the levels of urinary N-acetyl beta-D-glucosidase (NAG) and a1-microglobulin (a1-MG). The cause of ATIN was determined after renal biopsy according to the most likely cause cited by a nephrologist/pathologist group that included six nephrologists and two renal pathologists. All patients were screened for autoimmune diseases, malignancy and infectious diseases and accepted ophthalmological examinations to identify TINU syndrome during their hospital stay. Diagnoses of D-ATIN, TINU syndrome, Sjogren's syndrome and IgG4-related ATIN were made based on previously described criteria [20] [21] [22] [23] .
Follow-up, renal recovery, renal outcome and recurrent kidney injury During the follow-up periods, clinical assessments and laboratory tests such as urinalyses and SCr were routinely performed. Ocular examinations, renal tubular function and auto-antibodies were tested when needed. The cause of ATIN was reevaluated at every visit by the follow-up nephrologist group.
Renal recovery at 6 months post-biopsy was defined as follows: complete recovery indicated improvement in SCr level to within 25% of the baseline (or to 133 lmol/L if the baseline was not available). Partial recovery represented a >50% decrease in SCr level from its peak value but not reaching within 25% of its baseline value. No recovery was defined as the failure to meet the criteria for complete or partial recovery or remaining on renal replacement treatment (RRT). Renal outcomes were defined by the eGFRs at 12 months and at the end of follow-up. An eGFR !60 mL/min/1.73 m 2 was considered a good renal outcome, whereas an eGFR <60 mL/min/1.73 m 2 was defined as a poor renal outcome.
During the recovery phase, any acute increase in urinary levels of NAG by !2 times concurrent with an increase in SCr by !30% within 4 weeks was considered recurrent kidney injury. The cause of recurrent kidney injury was then determined by carefully investigating the patients' recent histories of infection, medications and systemic diseases, by evaluating the status of renal perfusion, and by performing B-scan ultrasound to exclude post-renal obstruction.
Statistical analysis
Continuous data are presented as the means with standard deviations (SDs) or median with interquartile ranges as appropriate. Categorical variables are presented as proportions. Comparisons among groups were conducted using one-way analysis of variance (ANOVA) or the KruskalWallis test for continuous variables and the chi-square test for categorical variables. Relevant covariates that might be associated with renal recovery (yes versus no) or long-term renal outcome (good versus poor) were analyzed with nonconditional logistic regression and odds ratios (ORs) with 95% confidence intervals (95% CIs), and P-values from the Wald chi-square test are reported. Covariates included in the multivariate analysis were age (per 10 years), gender (female versus male), causes of ATIN (D-ATIN, TINU, other autoimmune disease related), peak SCr (continuous, in renal recovery), valley eGFR (continuous, in renal outcome), interstitial inflammation score (ranked), interstitial fibrosis score (ranked), hypertension (yes versus no), diabetes (yes versus no) and follow-up course (continuous, in final outcome). Additional covariates that were selected by univariate analysis (P 0.1) before performing multivariate analysis included AKI (yes versus no), urinary microalbumin (continuous), urinary NAG (continuous), urinary a1-MG (continuous), uric acid (continuous), methylprednisolone pulse therapy (yes versus no), immunosuppressive medications (yes versus no, in renal outcome) and recurrent AKI (yes versus no, in renal outcome). The small number of patients with ATIN due to malignancy or other rare causes was not included in the analyses for renal recovery or long-term renal outcome. All P-values were two-sided, and a P-value <0.05 was considered significant. Analyses were conducted using the SPSS 20.0 Statistics software (SPSS, Inc., Chicago, IL, USA).
R E S U L T S
In all, 173 adult patients who were pathologically diagnosed with ATIN from 1 January 2005 to 31 December 2013, constituting 2.7% (173/6356) of the total native renal biopsies during the same period, were enrolled in the prospective cohort. A total of 157 cases (157/173, 90.8%) were followed up for at least 24 months (median 48 months, range 24-108 months) and were included in the current study ( Figure 1 ).
Etiology spectrum in patients with ATIN
As shown in Table 1 , at the time of renal biopsy, 64.3% of the cases (101/157) were identified as D-ATIN with definite histories of taking culprit drugs before the kidney injury and no evidence of uveitis or systemic diseases. Autoimmune diseases were responsible for 35 cases (22.3%), including TINU syndrome in 14 cases (8.9%) and 21 cases of other autoimmune diseases such as Sjogren's syndrome (15 cases, 9.6%), IgG4-related disease (5 cases, 3.2%) and sarcoidosis (1 case, 0.6%).
Among the 14 cases of TINU syndrome, 7 cases exhibited insidious uveitis during routine optical examination after biopsy. Uncommon causes included malignancy (6/157, 3 Figure 1 ). These reclassifications led to a change in the etiological spectrum of ATIN in this cohort of patients (Table 1) , with a decreased proportion of D-ATIN patients (79/157, 50.3%) and an increased percentage of autoimmune disease patients (65/157, 41.4%). Of the 35 patients whose final diagnosis was TINU syndrome, 60.0% (n ¼ 21) had late-onset uveitis (2-18 months post-renal biopsy) and were misclassified as D-ATIN, ATIN of unknown cause or Sjogren's syndrome at the time of renal biopsy.
Clinical-pathological characteristics of patients with ATIN
Of the 157 ATIN patients, the age of onset was 47.2612.7 years, and female patients predominated (65.6%). Common presenting symptoms included weakness (57.3%), nausea and vomiting (65.0%) and loss of weight (67.5%). The majority of the cases (123/157, 78.3%) were identified as AKD, 13 cases (8.3%) were classified as AKI and 21 cases (13.4%) were classified as CKD. The average time from the onset of symptoms or the detection of abnormal urinalysis or renal dysfunction to the diagnostic biopsy was 60 (30-90) days, indicating a generally delayed recognition and diagnosis of kidney injury.
The clinical-pathological features of ATIN are summarized in Tables 2 and 3 . Patients were grouped according to their final etiology diagnosis after follow-up. There was no significant difference in the severity of renal dysfunction or pathological changes between the patients with D-ATIN and those with TINU. Most patients with other autoimmune disease-related ATIN had sub-AKI and modest renal dysfunction, significantly elevated IgG levels and relatively lower values of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Male predominance and significantly elevated levels of serum uric acid were distinct features of patients with malignancy or other rare causes of ATIN.
Treatment and renal recovery at 6 months postdiagnostic biopsy
The treatment and renal recovery of ATIN is shown in Table  4 . Prednisone (30-40 mg/day) was prescribed in 91.1% of the patients, and methylprednisolone impulse was performed in 22.3%. In addition, 42.7% of the cases were prescribed additional immunosuppressive medications, such as mycophenolate, azathioprine and cyclophosphamide, due either to unresponsiveness to prednisone treatment or relapse of the disease during follow-up. Patients with D-ATIN had the best renal recovery, and those with ATIN related to rare causes had the poorest recovery. By 6 months after renal biopsy, complete or partial recovery was achieved in 83.5% of D-ATIN patients, 65.7% of TINU patients, 50.0% of patients with other autoimmune diseases and 14.3% of patients with rare causes (P ¼ 0.003). The restoration of renal function continued until 12 months post-renal biopsy in the patients with D-ATIN but not in the other groups ( Figure 2 ).
Correlates of poor recovery (partial or no recovery) were female gender (P ¼ 0.03), older age (P < 0.001), longer time from the onset of kidney injury to diagnostic biopsy (P ¼ 0.01) and higher degree of interstitial fibrosis (P ¼ 0.04). Patients with AKI (P < 0.001), higher peak SCr levels (P ¼ 0.004) or higher concentrations of urinary NAG (P ¼ 0.002) were more likely to have complete recovery by 6 months (Table 5) . On multivariable analysis, only older age (OR 3.06; 95% CI 1.74-5.41; P < 0.001) remained an independent risk factor for poor recovery, while urinary levels of NAG were found to be 
Age (years), mean (6 SD Table 3 . 16 Others included infection, metabolic disorder and toxins. c 154 cases were included in the analysis after excluding 3 cases who passed away during the first 3 months, including 2 cases with malignancy and 1 case with sepsis. an independent protective factor (OR 0.50; 95% CI 0.31-0.81; P ¼ 0.01) ( Table 5 ). Methylprednisolone impulse did not correlate with recovery status.
Recurrent kidney injury in ATIN resulted in elongated immunosuppressive therapy
Recurrent kidney injury was observed in 26.1% (n ¼ 41) of the ATIN patients (Table 4) and was common in patients with TINU (51.4%, often concomitant with active uveitis) and other autoimmune diseases (53.3%, usually asymptomatic). Most of the renewed increase in SCr occurred within 4-18 months postbiopsy when prednisone had been stopped (21 cases) or tapered to 2.5-10 mg/day (17 cases). Five cases had repeated kidney injury more than once (two to five times). Notably, six D-ATIN patients (7.6%) exhibited re-elevated SCr during follow-up when they had been taking medications including antibiotics, non-steroidal anti-inflammatory drugs and herbs. Increasing the dose of or reinitiating treatment with steroids yielded complete or partial recovery in 38 cases (92.7%). The recurrent kidney injury resulted in steroid therapy that was extended to 16 (5-31) months compared with five (4-6) months in those who had not. In 53 patients, mycophenolate (14 cases, 50-100 mg/ day for 6-12 months), azathioprine (13 cases, 50-100 mg/day for 6-12 months) or cyclophosphamide (26 cases, 50 mg/day, total 4-6 g) was prescribed to help taper and discontinue steroid treatment.
Renal outcomes and related factors
Altogether, five patients died within the first year postbiopsy, including four patients from malignancy and one from sepsis. By 12 months, decreased eGFR (<60 mL/min/1.73 m 2 ) was observed in 46.8% of D-ATIN patients, 74.3% of TINU patients, 56.7% of autoimmune disease patients and 100% of rare cause ATIN patients (P ¼ 0.003) ( Table 4 ). On Acute tubulointerstitial nephritis multivariable analysis, female gender (OR 5.39; 95% CI 1.15-5.28; P ¼ 0.03), poor recovery at 6 months (OR 12.04; 95% CI 2.56-56.59; P ¼ 0.002) and recurrent kidney injury during follow-up (OR 13.99; 95% CI 2.21-88.58; P ¼ 0.01) were independent risk factors for worse renal outcome. Those with higher nadir eGFRs had better renal outcomes (OR 0.55; 95% CI 0.32-0.95; P ¼ 0.03) ( Table 6 ). With extended follow-up, fewer patients with D-ATIN or TINU syndrome maintained eGFRs below 60 mL/min/1.73 m 2 (Table 4) , indicating a continuous restoration of renal function, even after 1 year post-biopsy in some cases. Except for the two cases with ATIN associated with hyperuricemia who developed end-stage renal disease at 36-48 months, none of the other patients had progressive CKD, with the eGFR changing at a rate of À0.18 (À1.89 to 0.93) mL/min/1.73 m 2 /year after 12 months post-biopsy.
D I S C U S S I O N
Defining the causes of ATIN is critical for developing proper treatment strategies. D-ATIN is thought to account for most ATIN cases (70-90%), according to recently published studies [1, 11, 13] . In our cohort, the proportion of D-ATIN was $70% if the patients did not receive routine ophthalmological examination at biopsy. During the course of follow-up, over one-fifth of the patients who were originally diagnosed with D-ATIN developed uveitis, systemic symptoms and auto-antibodies, so their ATIN etiology was redefined. A similar process was experienced by those who had been diagnosed with ATIN of unknown cause. In fact, our data indicate that a diagnosis of 'unknown cause' most likely means that the cause is not apparent at the time, and autoimmune diseases should always be taken into account. Therefore, this regularly followed-up cohort revealed a modified etiology spectrum of ATIN, with a decreased proportion of D-ATIN (64%!50%) and an increase in autoimmune disease-related ATIN (22%!41%). The proportion of patients with TINU syndrome, which is thought to be a rare cause of ATIN, increased from 9% at renal biopsy to 22% after follow-up, due to late-onset uveitis. These data suggest that autoimmune-related evidence could be present after kidney injury. More importantly, the patients with immunerelated ATIN were more likely to experience recurrent kidney injury than the D-ATIN patients, and they might require extended immunosuppressive therapy. These results demonstrate the importance of regular follow-up in defining the exact etiology of ATIN and providing the proper management of these patients. In addition, as the causes of ATIN varied according to age, gender and studies [4, 24] , the difference in the spectrum of etiologies of ATIN between our cohort and others may reflect variations among different populations.
Given the potential misdiagnosis as D-ATIN or ATIN with unknown cause at renal biopsy in patients with autoimmunerelated diseases in our cohort, it is critical for doctors to followup on evidence that may reflect or predict the underlying Disease course was defined as the interval between the onset of kidney injury and the diagnostic renal biopsy.
etiologies. The proportion of TINU patients increased from 5% to 9% after performing routine ocular examinations at renal biopsy in our ATIN cohort, since approximately half of the cases exhibited asymptomatic uveitis. Moreover, our previous studies have shown that the presence of membrane-bound complement regulatory protein (mCRP) auto-antibodies in ATIN patients could predict late-onset TINU syndrome [25, 26] . Our data also suggest that significantly elevated levels of IgG with relatively lower levels of systemic inflammatory responses could be associated with connective diseases such as Sjogren's syndrome and IgG4-related diseases. Additionally, markedly increased levels of serum uric acid indicate ATIN of rare causes, including malignancy, acute uric acid nephropathy and infection. Because proximal tubular dysfunction in ATIN usually impairs the reabsorption of uric acid, it causes hyperuricemia incompatible with diminished glomerular filtration, unless there is an additional change in uric acid production. Consistent with the literature [13] , patients with D-ATIN had the best renal recovery and maintained the best renal outcomes, followed by those patients with TINU, connective tissue diseases and rare causes in our study. Older age and delayed diagnosis were independent risk factors for poor renal outcomes. Notably, there was a generally delayed recognition and diagnosis of kidney injury in our patients, which certainly requires improvement. The delay in diagnosis might also be attributed to the subacute onset of renal dysfunction and the insidious clinical symptoms in some ATIN patients that, therefore, increase the difficulty in identifying the disease early for clinical practitioners. In our study, patients with higher urinary levels of NAG were more likely to achieve complete recovery and better renal outcomes, suggesting that urinary NAG might serve as a biomarker for reflecting ongoing active kidney injury requiring prompt treatment. These results demonstrate the importance of timely identification of ATIN in patients developing AKI, as prolonged exposure may result in a reduced chance of achieving full recovery.
Another important finding of our study is the recurrent kidney injury in ATIN during the follow-up course, which acts as an independent risk factor for worse renal outcomes. Such a repeated elevation in the SCr and urinary NAG levels occurred in over 50% of patients with TINU or autoimmune diseases and in 8% of D-ATIN patients who had been taking culprit drugs. Repeated acute lesions impede the restoration of kidney function and lead to chronic renal fibrosis [27] [28] [29] . More importantly, most patients with re-increased SCr were asymptomatic, and the reoccurrence would have gone undetected if the patients were not regularly followed up by nephrologists. The re-increased SCr might then cause progressive renal dysfunction. Our data reinforce the significant role of nephrology follow-up in improving the renal outcomes of patients with AKI [30] .
Most patients in our cohort with D-ATIN or autoimmunerelated ATIN received steroid treatment. Therefore, we were not able to define the contribution of steroids to renal recovery. Following multivariate analysis, methylprednisolone impulse was not related to either renal recovery at 6 months or longerterm renal outcomes. This finding was consistent with a recently published randomized controlled trial that showed an equal effectiveness of oral and pulse steroids in achieving remission at 3 months post-biopsy in 29 cases of D-ATIN [31] . In patients with recurrent kidney injury, steroid therapy was extended and additional immunosuppressive medications were prescribed. With the limitation of a nonrandomly controlled study, we cannot tell whether this treatment was effective in preventing relapse or in improving renal outcomes. Prospective randomized controlled trials are required to define the ideal management strategy for ATIN.
The main strength of our study is the prospective cohort design, including the regular follow-up and interventions by nephrologists in a large number of cases with ATIN. Selection bias originates from the single-center study and the inclusion of patients with biopsy-proven ATIN, which would affect the etiology spectrum of the disease entity. We might also fail to catch cases of milder kidney injury or patients with D-ATIN who achieved recovery after discontinuing the culprit medications, and we therefore may have underestimated the proportion of D-ATIN cases. Additionally, the commonly delayed diagnosis of kidney injury in our patients would lead to overestimations of worse renal outcomes due to this disease.
C O N C L U S I O N S
In summary, our data indicate that ATIN is a more complicated group of diseases than previously realized. The underlying autoimmune-related nature can be apparent months or years after the onset of ATIN, which might correlate with recurrent kidney injury and lead to poor renal outcomes. Therefore, regular follow-up is critical in defining the exact etiology and designing proper management strategies for patients with ATIN.
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